KPV 5 mg
Peptides

KPV 5 mg

Product Details Dragon Pharma
Active Substance KPV Lys-Pro-Val
Strength 5 mg per vial
Package 1 × 2 mL vial 5 mg labeled content
Form Lyophilized powder
Research Class Research peptide
Peptide Type Tripeptide α-MSH residues 11–13
Human Half-Life Not established
Development Status Preclinical
Out of stock

Dragon Pharma KPV: Advanced Research Peptide for Inflammation and Skin Health

Dragon Pharma introduces its high-purity KPV 5 mg, presented as a sterile lyophilized powder in a 2 mL vial. KPV, a tripeptide with the sequence Lysine-Proline-Valine, is a fragment of the larger alpha-melanocyte-stimulating hormone (α-MSH). It has become a significant compound in scientific research due to its potent anti-inflammatory and immunomodulatory properties, without the pigmentary effects associated with full-length α-MSH. For researchers investigating inflammatory pathways, skin conditions, and gut health, Dragon Pharma's KPV offers a reliable, precisely dosed tool. This comprehensive guide details its research applications, protocols, and synergistic potential within controlled laboratory settings.

Understanding KPV: Mechanism and Research Background

KPV is the C-terminal fragment (residues 11-13) of α-MSH. While α-MSH is known for its role in melanogenesis (pigmentation) and inflammation control, the KPV fragment has been isolated for its specific and powerful anti-inflammatory action. Its primary research interest lies in its ability to inhibit the activation of NF-κB, a key protein complex that controls DNA transcription and is a central mediator of the inflammatory response. By modulating this pathway, KPV can potentially reduce the production of pro-inflammatory cytokines like TNF-α and IL-6. Research referenced in biochemical databases such as PubMed Central highlights how specific peptide sequences can interact with inflammatory cascades. This makes KPV a valuable compound for studying conditions characterized by excessive inflammation, particularly in models of skin disorders (e.g., psoriasis, dermatitis) and intestinal inflammation (e.g., colitis).

KPV Effects in Research Models

In preclinical research, KPV has demonstrated a range of potential effects centered on inflammation control and tissue health. Its most pronounced effect is the potent reduction of localized and systemic inflammatory markers. This makes it a prime candidate for studies on inflammatory skin diseases, where it may help modulate immune response in dermal tissues. Secondly, KPV has shown promise in research models of gut barrier integrity and inflammatory bowel disease, where it may help soothe mucosal inflammation. For athletic and fitness research models, KPV's anti-inflammatory properties are of interest for studying exercise-induced inflammation, joint recovery, and the management of training-induced oxidative stress. Unlike corticosteroids, its action is highly targeted with a favorable safety profile in research models, presenting no risk of systemic immunosuppression or HPA axis suppression.

Technical Details

Peptide Type
Ξ±-MSH-Derived Tripeptide
Peptide Sequence
Lys-Pro-Val (KPV)
Peptide Length
3 Amino-Acid Residues
Structural Origin
Ξ±-MSH Residues 11–13
Parent Peptide
Ξ±-Melanocyte-Stimulating Hormone (Ξ±-MSH)
Molecular Formula
C₁₆H₃₀Nβ‚„Oβ‚„
Molecular Weight
342.4 g/mol
Research Status
Preclinical / Experimental

Dosage & Usage Guidelines

For research purposes, the Dragon Pharma KPV 5 mg vial is reconstituted with bacteriostatic water. Research dosages in animal models are notably low due to its high potency, typically ranging from 100 mcg to 500 mcg per day. A common research protocol involves daily administration, often via subcutaneous injection for systemic studies or topical application in dermatological research (when formulated appropriately). For localized skin research, it can be applied in a cream or serum base. The 5 mg vial provides ample material for extended research cycles. A standard approach is to begin at the lower end of the dosage range (100-200 mcg/day) and adjust based on observed inflammatory markers. Consistency in administration time and route is paramount for generating reproducible data.

Research Cycle Design and Synergistic Stacks

KPV research cycles are typically medium to long-term, ranging from 4 to 12 weeks, reflecting the chronic nature of inflammatory processes being studied. Its excellent tolerability allows for extended use in research models. To investigate comprehensive recovery, wellness, or performance enhancement, researchers often combine KPV with other Dragon Pharma compounds to create multifaceted study protocols:

  • For comprehensive tissue repair studies, combining KPV with the renowned healing peptide TB 500 can model synergistic effects on inflammation reduction and structural recovery.
  • In research focused on skin rejuvenation and collagen synthesis, stacking KPV with copper peptide GHK-Cu 50 mg allows investigation into anti-inflammatory and regenerative pathways.
  • For studies on gut-brain axis or cognitive recovery from stress, KPV can be paired with the nootropic peptide Selank 10 mg.
  • In body composition research where inflammation is a variable, combining KPV with the selective androgen receptor modulator LGD 4033 can help isolate anti-catabolic and anti-inflammatory effects.
  • For advanced metabolic and longevity research models, KPV may be used alongside mitochondrial protectants like SS-31 50 mg to study combined effects on cellular stress and inflammation.

Possible Side Effects and Research Safety

In animal research models, KPV is exceptionally well-tolerated at standard research doses. Given its anti-inflammatory nature, it presents virtually no risk of the side effects common to anabolic steroids (water retention, hypertension, hepatotoxicity). There is no androgenic, estrogenic, or progestogenic activity. The most frequently noted observations in research are mild and transient, potentially including slight redness at the injection site if administered subcutaneously. In topical skin research, it is generally non-irritating. Its mechanism suggests it may actually benefit conditions like acne by reducing inflammatory lesions. Researchers must always employ aseptic techniques during reconstitution and administration to prevent contamination.

Half-Life, Detection, and Pharmacokinetics

KPV, like many small peptides, has a relatively short plasma half-life, estimated to be between 2 to 4 hours. This supports daily or even twice-daily administration in research protocols to maintain consistent plasma levels for systemic studies. Its rapid metabolism means it has an extremely short detection time and is broken down into its constituent amino acids quickly, leaving no long-term trace or signature detectable in standard drug screens. This pharmacokinetic profile is advantageous for research requiring precise control over compound exposure timing.

Topical vs. Systemic Research Applications

A key advantage of KPV in research is its versatility in administration routes. Systemic Administration (subcutaneous injection) is used for studying whole-body anti-inflammatory effects, gut health, and systemic immune modulation. Topical Administration is the preferred route for dermatological research. When formulated into a suitable vehicle (e.g., a cream containing pentosan polysulfate or other carriers noted in literature), KPV can be applied directly to skin models to study conditions like psoriasis, acne, rosacea, or general anti-aging effects on skin inflammation. This dual-application potential significantly broadens its utility in scientific investigation.

Why Choose Dragon Pharma for Your KPV Research?

Selecting Dragon Pharma ensures access to a peptide of uncompromised quality. Our KPV 5 mg is synthesized to >99% purity, verified by independent HPLC-MS analysis. Each batch is tested for sterility and the absence of endotoxins, guaranteeing it meets the strict standards required for sensitive research. We provide secure, discreet shipping directly from our USA warehouse, ensuring your research materials arrive promptly and in optimal condition. Trust in Dragon Pharma's reputation for excellence to supply the foundational compounds for your groundbreaking research into inflammation and healing.

Shipping & Product Authenticity

USA Domestic
4–5 business days
International
13–15 business days
Order Processing
24–48 business hours
Tracking
Tracking number provided
Direct Supply & Discreet Delivery

This product is supplied through the official Dragon Pharma distribution chain and shipped in original manufacturer packaging. The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details.

What to Expect

  • βœ” Orders are processed after payment confirmation
  • βœ” USA Domestic shipping is typically faster when local stock is selected
  • βœ” International orders include tracking, though update frequency may vary by destination
  • βœ” Multiple warehouses may result in separate shipments when applicable
Authenticity support: official Dragon Pharma presentation, batch-linked lab proof, and original packaging help reinforce product legitimacy and buyer confidence.
Verified Supply

For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.

Storage

Store the lyophilized powder at controlled room temperature (15–25°C) in a dry, dark place, away from direct light and moisture. The unopened vial should be kept in its original packaging to maintain stability.

After reconstitution, store the solution at 2–8°C and use within 14 days. Do not freeze. Discard any unused portion after the recommended storage period. Before use, inspect the solution and avoid use if it appears cloudy, discolored, or contains particulate matter, or if the vial or seal is compromised.

Keep out of reach of children. Follow proper handling and sterile injection practices during research use.

Proper storage conditions help maintain product stability and consistent performance across the product's shelf life.

Frequently Asked Questions

What is the main research purpose of KPV peptide?

The primary research focus for KPV is its potent anti-inflammatory and immunomodulatory properties. It is extensively studied in models of inflammatory skin conditions (psoriasis, dermatitis, acne), intestinal inflammation (colitis), and general models of localized inflammation. Its mechanism involves inhibiting key pro-inflammatory pathways like NF-ΞΊB activation, making it a valuable tool for inflammation-focused research.

Can KPV be used topically in research, and how is it prepared?

Yes, topical application is a major route in dermatological research. To prepare a topical research solution, the lyophilized KPV powder is reconstituted with sterile water or a specific carrier like pentosan polysulfate solution mentioned in literature. This solution is then mixed into a neutral, preservative-free cream base at a specified concentration (e.g., 1-5%). This allows for direct application to skin models to study localized anti-inflammatory effects.

How does KPV differ from other anti-inflammatory peptides like BPC-157?

While both have anti-inflammatory properties, their mechanisms and primary research applications differ. BPC-157 is a gastric-derived peptide researched primarily for systemic healing of tendons, ligaments, and the GI tract, promoting angiogenesis. KPV is a fragment of Ξ±-MSH specifically researched for directly suppressing NF-ΞΊB-driven inflammation, making it more targeted for skin and mucosal inflammatory conditions. They can be complementary in research on healing.

What is a typical research cycle length for KPV?

Given that inflammatory conditions are often chronic, research cycles with KPV tend to be longer, typically ranging from 6 to 12 weeks in experimental models. For acute inflammation models, shorter cycles of 2-4 weeks may be used. Its high tolerability profile supports extended administration in research settings without the toxicities associated with long-term steroid or NSAID use in models.

Is KPV suppressive to the HPTA or does it require a PCT?

No, KPV has no interaction with the hypothalamic-pituitary-testicular axis (HPTA). It does not influence sex hormone production, receptor binding, or feedback loops. Therefore, it is not suppressive in the way that androgenic anabolic steroids are, and a Post Cycle Therapy (PCT) protocol involving SERMs like Clomid or Nolvadex is completely unnecessary and irrelevant following a KPV research cycle.

No reviews found

Please log in to write KPV 5 mg review.

Related Offers
Kalpatropin HGH 200 IU
Kalpa Pharmaceuticals LTD, India
Product Details Kalpa Pharmaceuticals
Active Substance Somatropin Recombinant human growth hormone
Strength 20 IU/vial
Package 10 × 2 mL vials 200 IU total labeled content
Form Lyophilized powder For reconstitution
Drug Class Human growth hormone
Protein Length 191 amino acids
Hormone Type Recombinant hGH
Technology Recombinant DNA
Out of stock
Shipped International
FERTIGYN 5000 IU
Sun Pharma, India

CLASSIFICATION: PEPTIDE HORMONE / HCG
ACTIVE SUBSTANCE: HUMAN CHORIONIC GONADOTROPIN
FORM: 1 ML AMP x 5000 IU
ACTIVE HALF-LIFE: ~3–6 DAYS
DOSAGE: 250–1000 IU 2–3x/WEEK (ON-CYCLE or PCT)
ACNE: POSSIBLE
WATER RETENTION: MODERATE
HIGH BLOOD PRESSURE (HBP): UNLIKELY
HEPATOTOXICITY: NONE
AROMATIZATION: INDIRECTLY ELEVATES ESTROGEN
MANUFACTURER: SUN PHARMA

$70.00
Shipped International
HUCOG 10000 IU
Bharat Serums And Vaccines Ltd, India

CLASSIFICATION: PEPTIDE HORMONE / HCG
ACTIVE SUBSTANCE: PRE-MIXED HUMAN CHORIONIC GONADOTROPIN
FORM: 1 VIAL x 10000 IU (READY-TO-INJECT)
ACTIVE HALF-LIFE: ~3–6 DAYS
DOSAGE: 250–1000 IU 2–3x/WEEK (ON-CYCLE or PCT)
ACNE: POSSIBLE
WATER RETENTION: LOW to MODERATE
HIGH BLOOD PRESSURE (HBP): RARE
HEPATOTOXICITY: NONE
AROMATIZATION: INDIRECTLY INCREASES ESTROGEN
MANUFACTURER: BHARAT SERUMS AND VACCINES

$90.00
Shipped International
HUCOG 5000 IU
Bharat Serums And Vaccines Ltd, India

CLASSIFICATION: PEPTIDE HORMONE / HCG
ACTIVE SUBSTANCE: PRE-MIXED HUMAN CHORIONIC GONADOTROPIN
FORM: 1 VIAL x 5000 IU (READY-TO-INJECT)
ACTIVE HALF-LIFE: ~3–6 DAYS
DOSAGE: 250–1000 IU 2–3x/WEEK (ON-CYCLE or PCT)
ACNE: POSSIBLE
WATER RETENTION: LOW to MODERATE
HIGH BLOOD PRESSURE (HBP): RARE
HEPATOTOXICITY: NONE
AROMATIZATION: INDIRECTLY INCREASES ESTROGEN
MANUFACTURER: BHARAT SERUMS AND VACCINES

$70.00
Lab Tested
Shipped International
HCG 5000 IU
Dragon Pharma, Europe
Product Details Dragon Pharma
Active Substance Human Chorionic Gonadotropin hCG
Strength 5,000 IU per vial
Package 1 × 2 mL vial Plus 1 solvent ampoule
Form Lyophilized powder For reconstitution
Drug Class Gonadotropin hormone
Biological Activity LH receptor agonist
Estimated Half-Life Approximately 24–36 hours
Water Retention Possible
Latest laboratory result 4,768 IU September 26, 2023 · 95.36% of 5,000 IU label claim View
$75.00

Add to Cart - Product(s)

Close Button
Empty

Total Cost: